A randomized, open-label study of the effect of two different dosages of PEGASYS [peginterferon alfa-2a] monotherapy on sustained virologic response in hemodialysis patients with chronic hepatitis C and end-stage renal disease.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 03 Jun 2010 Roche website has reported planned number of patients as 85.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 11 Apr 2007 Interim results have been reported.